Age Range: 35-98 years

Size: 24,325 subjects


Data Collection: 2005-ongoing; 2017-ongoing (recall, n =2,573); 2005-2015 (follow-up record linkage with regional health registries)

Study population:General population (age ≥35 year, 48% men)

Recruitment: Molise region, Italy

Biological Samples: Citrated plasma, EDTA plasma, serum, cellular pellet, DNA and urinary spots (over 700,000 samples in a dedicated biobank, Molibank, within and BBRMI-ERIC networks)

Brain Imaging: Magnetic Resonance imaging (sub-sample about 3,000 subjects)

Baseline Clinical assessment:

  • Anthropometric, blood pressure, electrocardiogram and spirometric test (pulmonary diffusion capacity, gas diffusion and pulmonary volumes through plethysmography);
  • Blood glucose, cholesterol, HDL, LDL, C-reactive protein, D-Dimers and blood cell count, Apoliprotein A, Apoliprotein B, C-peptide, Creatinine, Cystatin C, Glucose, HDL, Insulin, LDL, Lipoprotein(a), N-terminal-pro B-type natriuretic peptide, Testosterone, Triglycerides, hs Troponin I, Vitamin D, uric Acid, ALT, AST, albumin, fibinogen, ATIII;
  • SF36 health survey, psychometric tests to evaluate any depressive status, stress response and attitude to suicide and resilience;
  • Risk factors: social status, physical activity, dietary habits, smoking habits, hormonal status in women, body weight history, history of hypertension, diabetes and dyslipidemia and relative pharmacological treatment (linkage with Regional Drug Registry)


Recall Clinical assessment: the same assessment of baseline plus MoCaTest,  Smell, Hearing, Taste, Frailty assessment in over 65 years, sleep quality questionnaire, bone density.

Diseases studied at follow-up

  • Cerebrovascular disease
  • Parkinson disease
  • Alzheimer disease
  • Dementia
  • Multiple sclerosis
  • CVD
  • Cancer
  • Total and cause-specific mortality

Country: Italy